Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Abstract Results from Blinded Buprenorphine OR Neonatal morphine solution (BBORN), a previous phase III trial in infants with neonatal opioid withdrawal syndrome (NOWS), demonstrated that sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than th...
Enregistré dans:
Auteurs principaux: | Rena Eudy‐Byrne, Nicole Zane, Susan C. Adeniyi‐Jones, Marc R. Gastonguay, Ana Ruiz‐Garcia, Gagan Kushal, Walter K. Kraft |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/36acd5d7a6f74a369d135df943dae29b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Characterization of neonatal opioid withdrawal syndrome in Arizona from 2010-2017.
par: Emery R Eaves, et autres
Publié: (2021) -
Metaheuristics for pharmacometrics
par: Seongho Kim, et autres
Publié: (2021) -
Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
par: Michael Soyka
Publié: (2021) -
Elucidating the context for implementing nonpharmacologic care for neonatal opioid withdrawal syndrome: a qualitative study of perinatal nurses
par: Clayton J. Shuman, et autres
Publié: (2021) - CPT: Pharmacometrics & Systems Pharmacology